Skip to main content
Journal cover image

Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival.

Publication ,  Journal Article
Onaitis, MW; Noone, RB; Fields, R; Hurwitz, H; Morse, M; Jowell, P; McGrath, K; Lee, C; Anscher, MS; Clary, B; Mantyh, C; Pappas, TN ...
Published in: Ann Surg Oncol
December 2001

BACKGROUND: Up to 30% of patients with locally advanced rectal cancer have a complete clinical or pathologic response to neoadjuvant chemoradiation. This study analyzes complete clinical and pathologic responders among a large group of rectal cancer patients treated with neoadjuvant chemoradiation. METHODS: From 1987 to 2000, 141 consecutive patients with biopsy-proven, locally advanced rectal cancer were treated with preoperative 5-fluorouracil-based chemotherapy and radiation. Clinical restaging after treatment consisted of proctoscopic examination and often computed tomography scan. One hundred forty patients then underwent operative resection, with results tracked in a database. Standard statistical methods were used to examine the outcomes of those patients with complete clinical or pathologic responses. RESULTS: No demographic differences were detected between either clinical complete and clinical partial responders or pathologic complete and pathologic partial responders. The positive predictive value of clinical restaging was 60%, and accuracy was 82%. By use of the Kaplan-Meier life table analysis, clinical complete responders had no advantage in local recurrence, disease-free survival, or overall survival rates when compared with clinical partial responders. Pathologic complete responders also had no recurrence or survival advantage when compared with pathologic partial responders. Of the 34 pathologic T0 tumors, 4 (13%) had lymph node metastases. CONCLUSIONS: Clinical assessment of complete response to neoadjuvant chemoradiation is unreliable. Micrometastatic disease persists in a proportion of patients despite pathologic complete response. Observation or local excision for patients thought to be complete responders should be undertaken with caution.

Duke Scholars

Published In

Ann Surg Oncol

DOI

ISSN

1068-9265

Publication Date

December 2001

Volume

8

Issue

10

Start / End Page

801 / 806

Location

United States

Related Subject Headings

  • Survival Rate
  • Rectal Neoplasms
  • Radiotherapy, Adjuvant
  • Radiotherapy Dosage
  • Oncology & Carcinogenesis
  • Neoplasm, Residual
  • Middle Aged
  • Male
  • Humans
  • Fluorouracil
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Onaitis, M. W., Noone, R. B., Fields, R., Hurwitz, H., Morse, M., Jowell, P., … Tyler, D. S. (2001). Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol, 8(10), 801–806. https://doi.org/10.1007/s10434-001-0801-2
Onaitis, M. W., R. B. Noone, R. Fields, H. Hurwitz, M. Morse, P. Jowell, K. McGrath, et al. “Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival.Ann Surg Oncol 8, no. 10 (December 2001): 801–6. https://doi.org/10.1007/s10434-001-0801-2.
Onaitis MW, Noone RB, Fields R, Hurwitz H, Morse M, Jowell P, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol. 2001 Dec;8(10):801–6.
Onaitis, M. W., et al. “Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival.Ann Surg Oncol, vol. 8, no. 10, Dec. 2001, pp. 801–06. Pubmed, doi:10.1007/s10434-001-0801-2.
Onaitis MW, Noone RB, Fields R, Hurwitz H, Morse M, Jowell P, McGrath K, Lee C, Anscher MS, Clary B, Mantyh C, Pappas TN, Ludwig K, Seigler HF, Tyler DS. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol. 2001 Dec;8(10):801–806.
Journal cover image

Published In

Ann Surg Oncol

DOI

ISSN

1068-9265

Publication Date

December 2001

Volume

8

Issue

10

Start / End Page

801 / 806

Location

United States

Related Subject Headings

  • Survival Rate
  • Rectal Neoplasms
  • Radiotherapy, Adjuvant
  • Radiotherapy Dosage
  • Oncology & Carcinogenesis
  • Neoplasm, Residual
  • Middle Aged
  • Male
  • Humans
  • Fluorouracil